0000950170-24-001295.txt : 20240103 0000950170-24-001295.hdr.sgml : 20240103 20240103183023 ACCESSION NUMBER: 0000950170-24-001295 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Prout Samantha CENTRAL INDEX KEY: 0001743122 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 24508859 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER NAME: FORMER CONFORMED NAME: Prout Samantha Whiteman DATE OF NAME CHANGE: 20180607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (215) 921-7600 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0508 4 2023-12-31 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001743122 Prout Samantha 47 HULFISH STREET PRINCETON NJ 08542 false true false false Chief Accounting Officer false Common Stock 2023-12-31 4 F false 23356 14.19 D 98556 D Common Stock 2024-01-02 4 A false 25252 0.0 A 123808 D Common Stock 2024-01-02 4 F false 1313 14.24 D 122495 D Stock Options (right to buy) 14.24 2024-01-02 4 A false 43592 0 A 2034-01-02 Common Stock 43592 43592 D Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 2, 2025 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. /s/ Christian Formica, Attorney-in-Fact 2024-12-03